R-Zero engaged an independent clinical testing lab to validate the efficacy of its Far UV disinfection device, Vive, against human coronavirus, MRSA, MRSE, Klebsiella aerogenes, and Aspergillus brasiliensis. R-Zero selected microorganisms endemic to the environments Vive will be used in, ensuring partners understand Vive’s efficacy against the microorganisms most important to them. T
Highlights
R-Zero Vive accomplished:
- 4-log (99.99%) reduction in airborne bacteria and viruses in 90 minutes.
- >2-log (99%) reduction in airborne grey-mold spores.
- >6 eACH in ~100 sq ft room for T1 Bacteriophage (SARS-CoV-2 surrogate)
|
Species |
# of Trials |
Trial Time |
Data Type |
Trial 1 |
Trial 2 |
Trial 3 |
|
T1 Bacteriophage |
3 |
120 |
Net Log Reduction |
4.41 |
4.04 |
4.18 |
|
Net % Reduction |
99.9961% |
99.9908% |
99.9934% |
|||
|
Staphylococcus epidermidis |
3 |
120 |
Net Log Reduction |
4.85 |
4.85 |
4.47 |
|
Net % Reduction |
99.9986% |
99.9986% |
99.9966% |
|||
|
Klebsiella aerogenes |
3 |
90 |
Net Log Reduction |
4.89 |
4.94 |
5.14 |
|
Net % Reduction |
99.9987% |
99.9988% |
99.9993% |
|||
|
Aspergillus brasiliensis (Spore forming mold) |
3 |
240 |
Net Log Reduction |
2.53 |
2.81 |
2.72 |
|
Net % Reduction |
99.7018% |
99.8443% |
99.8080% |
Link to Third Party Lab Testing